Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) kicked off on Monday, down -5.44% from the previous trading day, before settling in for the closing price of $13.42. Over the past 52 weeks, AMLX has traded in a range of $2.60-$15.15.
During the last 5-year period, the sales drop of Healthcare Sector giant was -78.71%. While this was happening, its average annual earnings per share was recorded 62.09%. With a float of $79.68 million, this company’s outstanding shares have now reached $89.16 million.
Let’s determine the extent of company efficiency that accounts for 123 employees.
Amylyx Pharmaceuticals Inc (AMLX) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Amylyx Pharmaceuticals Inc is 25.39%, while institutional ownership is 70.85%. The most recent insider transaction that took place on Sep 30 ’25, was worth 430,952. In this transaction Co-Chief Executive Officer of this company sold 29,975 shares at a rate of $14.38, taking the stock ownership to the 3,325,301 shares. Before that another transaction happened on Sep 30 ’25, when Company’s Chief Legal Officer sold 8,828 for $14.58, making the entire transaction worth $128,669. This insider now owns 148,141 shares in total.
Amylyx Pharmaceuticals Inc (AMLX) Recent Fiscal highlights
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -1.07 earnings per share (EPS), lower than consensus estimate (set at -0.92) by -0.16. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.39 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 62.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 30.99% during the next five years compared to -78.71% drop over the previous five years of trading.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Trading Performance Indicators
Take a look at Amylyx Pharmaceuticals Inc’s (AMLX) current performance indicators. Last quarter, stock had a quick ratio of 8.72.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.50, a number that is poised to hit -0.45 in the next quarter and is forecasted to reach -1.31 in one year’s time.
Technical Analysis of Amylyx Pharmaceuticals Inc (AMLX)
Looking closely at Amylyx Pharmaceuticals Inc (NASDAQ: AMLX), its last 5-days average volume was 2.27 million, which is a jump from its year-to-date volume of 1.26 million. As of the previous 9 days, the stock’s Stochastic %D was 22.02%.
During the past 100 days, Amylyx Pharmaceuticals Inc’s (AMLX) raw stochastic average was set at 77.57%, which indicates a significant increase from 22.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.89 in the past 14 days, which was higher than the 0.53 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.36, while its 200-day Moving Average is $6.05. However, in the short run, Amylyx Pharmaceuticals Inc’s stock first resistance to watch stands at $13.55. Second resistance stands at $14.42. The third major resistance level sits at $15.02. If the price goes on to break the first support level at $12.08, it is likely to go to the next support level at $11.48. Now, if the price goes above the second support level, the third support stands at $10.61.
Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) Key Stats
The company with the Market Capitalisation of 1.35 billion has total of 89,167K Shares Outstanding. Its annual sales at the moment are 87,370 K in contrast with the sum of -301,740 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -41,440 K.
